1
|
Xu G, Torri D, Cuesta-Hoyos S, Panda D, Yates LRL, Zallot R, Bian K, Jia D, Iorgu AI, Levy C, Shepherd SA, Micklefield J. Cryptic enzymatic assembly of peptides armed with β-lactone warheads. Nat Chem Biol 2024:10.1038/s41589-024-01657-7. [PMID: 38951647 DOI: 10.1038/s41589-024-01657-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2023] [Accepted: 05/29/2024] [Indexed: 07/03/2024]
Abstract
Nature has evolved biosynthetic pathways to molecules possessing reactive warheads that inspired the development of many therapeutic agents, including penicillin antibiotics. Peptides armed with electrophilic warheads have proven to be particularly effective covalent inhibitors, providing essential antimicrobial, antiviral and anticancer agents. Here we provide a full characterization of the pathways that nature deploys to assemble peptides with β-lactone warheads, which are potent proteasome inhibitors with promising anticancer activity. Warhead assembly involves a three-step cryptic methylation sequence, which is likely required to reduce unfavorable electrostatic interactions during the sterically demanding β-lactonization. Amide-bond synthetase and adenosine triphosphate (ATP)-grasp enzymes couple amino acids to the β-lactone warhead, generating the bioactive peptide products. After reconstituting the entire pathway to β-lactone peptides in vitro, we go on to deliver a diverse range of analogs through enzymatic cascade reactions. Our approach is more efficient and cleaner than the synthetic methods currently used to produce clinically important warhead-containing peptides.
Collapse
Affiliation(s)
- Guangcai Xu
- Department of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK
| | - Daniele Torri
- Department of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK
| | - Sebastian Cuesta-Hoyos
- Department of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK
| | - Deepanjan Panda
- Department of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK
| | - Luke R L Yates
- Department of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK
| | - Rémi Zallot
- Department of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK
| | - Kehan Bian
- Department of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK
| | - Dongxu Jia
- Department of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK
| | - Andreea I Iorgu
- Department of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK
| | - Colin Levy
- Department of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK
| | - Sarah A Shepherd
- Department of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK
| | - Jason Micklefield
- Department of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK.
| |
Collapse
|
2
|
Embo-Ibouanga AW, Nguyen M, Joly JP, Coustets M, Augereau JM, Paloque L, Vanthuyne N, Bikanga R, Robert A, Benoit-Vical F, Audran G, Mellet P, Boissier J, Marque SRA. Peptide-Alkoxyamine Drugs: An Innovative Approach to Fight Schistosomiasis: "Digging Their Graves with Their Forks". Pathogens 2024; 13:482. [PMID: 38921780 PMCID: PMC11206678 DOI: 10.3390/pathogens13060482] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2024] [Revised: 05/23/2024] [Accepted: 05/24/2024] [Indexed: 06/27/2024] Open
Abstract
The expansion of drug resistant parasites sheds a serious concern on several neglected parasitic diseases. Our recent results on cancer led us to envision the use of peptide-alkoxyamines as a highly selective and efficient new drug against schistosome adult worms, the etiological agents of schistosomiasis. Indeed, the peptide tag of the hybrid compounds can be hydrolyzed by worm's digestive enzymes to afford a highly labile alkoxyamine which homolyzes spontaneously and instantaneously into radicals-which are then used as a drug against Schistosome adult parasites. This approach is nicely summarized as digging their graves with their forks. Several hybrid peptide-alkoxyamines were prepared and clearly showed an activity: two of the tested compounds kill 50% of the parasites in two hours at a concentration of 100 µg/mL. Importantly, the peptide and alkoxyamine fragments that are unable to generate alkyl radicals display no activity. This strong evidence validates the proposed mechanism: a specific activation of the prodrugs by the parasite proteases leading to parasite death through in situ alkyl radical generation.
Collapse
Affiliation(s)
- Ange W. Embo-Ibouanga
- Aix-Marseille University, CNRS, UMR 7273, Case 551, Avenue Escadrille Normandie-Niemen, CEDEX 20, 13397 Marseille, France; (A.W.E.-I.); (J.-P.J.)
| | - Michel Nguyen
- Laboratoire de Chimie de Coordination (LCC-CNRS) and, New Antimalarial Molecules and Pharmacological Approaches (MAAP), Inserm ERL 1289, Université de Toulouse, CNRS, 31077 Toulouse, France; (M.N.); (M.C.); (J.-M.A.); (L.P.); (A.R.); (F.B.-V.)
- Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III—Paul Sabatier (UPS), 31077 Toulouse, France
| | - Jean-Patrick Joly
- Aix-Marseille University, CNRS, UMR 7273, Case 551, Avenue Escadrille Normandie-Niemen, CEDEX 20, 13397 Marseille, France; (A.W.E.-I.); (J.-P.J.)
| | - Mathilde Coustets
- Laboratoire de Chimie de Coordination (LCC-CNRS) and, New Antimalarial Molecules and Pharmacological Approaches (MAAP), Inserm ERL 1289, Université de Toulouse, CNRS, 31077 Toulouse, France; (M.N.); (M.C.); (J.-M.A.); (L.P.); (A.R.); (F.B.-V.)
- Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III—Paul Sabatier (UPS), 31077 Toulouse, France
| | - Jean-Michel Augereau
- Laboratoire de Chimie de Coordination (LCC-CNRS) and, New Antimalarial Molecules and Pharmacological Approaches (MAAP), Inserm ERL 1289, Université de Toulouse, CNRS, 31077 Toulouse, France; (M.N.); (M.C.); (J.-M.A.); (L.P.); (A.R.); (F.B.-V.)
- Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III—Paul Sabatier (UPS), 31077 Toulouse, France
| | - Lucie Paloque
- Laboratoire de Chimie de Coordination (LCC-CNRS) and, New Antimalarial Molecules and Pharmacological Approaches (MAAP), Inserm ERL 1289, Université de Toulouse, CNRS, 31077 Toulouse, France; (M.N.); (M.C.); (J.-M.A.); (L.P.); (A.R.); (F.B.-V.)
- Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III—Paul Sabatier (UPS), 31077 Toulouse, France
| | - Nicolas Vanthuyne
- Aix-Marseille University, CNRS, Centrale Marseille ISM2, Case 531, Avenue Escadrille Normandie-Niemen, CEDEX 20, 13397 Marseille, France
| | - Raphaël Bikanga
- Université des Sciences et Techniques de Masuku, LASNSOM, Franceville BP 901, Gabon;
| | - Anne Robert
- Laboratoire de Chimie de Coordination (LCC-CNRS) and, New Antimalarial Molecules and Pharmacological Approaches (MAAP), Inserm ERL 1289, Université de Toulouse, CNRS, 31077 Toulouse, France; (M.N.); (M.C.); (J.-M.A.); (L.P.); (A.R.); (F.B.-V.)
| | - Françoise Benoit-Vical
- Laboratoire de Chimie de Coordination (LCC-CNRS) and, New Antimalarial Molecules and Pharmacological Approaches (MAAP), Inserm ERL 1289, Université de Toulouse, CNRS, 31077 Toulouse, France; (M.N.); (M.C.); (J.-M.A.); (L.P.); (A.R.); (F.B.-V.)
- Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III—Paul Sabatier (UPS), 31077 Toulouse, France
| | - Gérard Audran
- Aix-Marseille University, CNRS, UMR 7273, Case 551, Avenue Escadrille Normandie-Niemen, CEDEX 20, 13397 Marseille, France; (A.W.E.-I.); (J.-P.J.)
| | - Philippe Mellet
- Magnetic Resonance of Biological Systems, UMR 5536 CNRS-University of Bordeaux, 146 rue Leo Saignat, CEDEX, 33076 Bordeaux, France
- INSERM, 146 rue Leo Saignat, CEDEX, 33076 Bordeaux, France
| | - Jérôme Boissier
- IHPE, CNRS, Ifremer, University Perpignan Via Domitia, 66860 Perpignan, France
| | - Sylvain R. A. Marque
- Aix-Marseille University, CNRS, UMR 7273, Case 551, Avenue Escadrille Normandie-Niemen, CEDEX 20, 13397 Marseille, France; (A.W.E.-I.); (J.-P.J.)
| |
Collapse
|
3
|
Illigmann A, Vielberg MT, Lakemeyer M, Wolf F, Dema T, Stange P, Kuttenlochner W, Liebhart E, Kulik A, Staudt ND, Malik I, Grond S, Sieber SA, Kaysser L, Groll M, Brötz-Oesterhelt H. Structure of Staphylococcus aureus ClpP Bound to the Covalent Active-Site Inhibitor Cystargolide A. Angew Chem Int Ed Engl 2024; 63:e202314028. [PMID: 38029352 DOI: 10.1002/anie.202314028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2023] [Revised: 11/27/2023] [Accepted: 11/28/2023] [Indexed: 12/01/2023]
Abstract
The caseinolytic protease is a highly conserved serine protease, crucial to prokaryotic and eukaryotic protein homeostasis, and a promising antibacterial and anticancer drug target. Herein, we describe the potent cystargolides as the first natural β-lactone inhibitors of the proteolytic core ClpP. Based on the discovery of two clpP genes next to the cystargolide biosynthetic gene cluster in Kitasatospora cystarginea, we explored ClpP as a potential cystargolide target. We show the inhibition of Staphylococcus aureus ClpP by cystargolide A and B by different biochemical methods in vitro. Synthesis of semisynthetic derivatives and probes with improved cell penetration allowed us to confirm ClpP as a specific target in S. aureus cells and to demonstrate the anti-virulence activity of this natural product class. Crystal structures show cystargolide A covalently bound to all 14 active sites of ClpP from S. aureus, Aquifex aeolicus, and Photorhabdus laumondii, and reveal the molecular mechanism of ClpP inhibition by β-lactones, the predominant class of ClpP inhibitors.
Collapse
Affiliation(s)
- Astrid Illigmann
- Department of Microbial Bioactive Compounds, Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen, Auf der Morgenstelle 28, 72076, Tübingen, Germany
| | - Marie-Theres Vielberg
- Chair of Biochemistry, Centre for Protein Assemblies, Technical University Munich, Ernst-Otto-Fischer-Strasse 8, 85748, Garching, Germany
| | - Markus Lakemeyer
- Chair of Organic Chemistry II, Technical University Munich, School of Natural Sciences, Center for Functional Protein Assemblies (CPA), Ernst-Otto-Fischer-Straße 8/I, 85748, Garching b.München, Germany
- Current address: Institute of Organic Chemistry and Macromolecular Chemistry, Friedrich Schiller University Jena, Humboldtstrasse 10, 07743, Jena, Germany
| | - Felix Wolf
- Synthetic Biology of Anti-infective Agents, Pharmaceutical Institute, University of Tübingen, Auf der Morgenstelle 8, 72076, Tübingen, Germany
| | - Taulant Dema
- Institute of Organic Chemistry, University of Tübingen, Auf der Morgenstelle 18, 72076, Tübingen, Germany
| | - Patrik Stange
- Institute of Organic Chemistry, University of Tübingen, Auf der Morgenstelle 18, 72076, Tübingen, Germany
| | - Wolfgang Kuttenlochner
- Chair of Biochemistry, Centre for Protein Assemblies, Technical University Munich, Ernst-Otto-Fischer-Strasse 8, 85748, Garching, Germany
| | - Elisa Liebhart
- Department of Microbial Bioactive Compounds, Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen, Auf der Morgenstelle 28, 72076, Tübingen, Germany
| | - Andreas Kulik
- Department of Microbial Bioactive Compounds, Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen, Auf der Morgenstelle 28, 72076, Tübingen, Germany
| | - Nicole D Staudt
- Synthetic Biology of Anti-infective Agents, Pharmaceutical Institute, University of Tübingen, Auf der Morgenstelle 8, 72076, Tübingen, Germany
| | - Imran Malik
- Department of Microbial Bioactive Compounds, Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen, Auf der Morgenstelle 28, 72076, Tübingen, Germany
| | - Stephanie Grond
- Institute of Organic Chemistry, University of Tübingen, Auf der Morgenstelle 18, 72076, Tübingen, Germany
| | - Stephan A Sieber
- Chair of Organic Chemistry II, Technical University Munich, School of Natural Sciences, Center for Functional Protein Assemblies (CPA), Ernst-Otto-Fischer-Straße 8/I, 85748, Garching b.München, Germany
| | - Leonard Kaysser
- Synthetic Biology of Anti-infective Agents, Pharmaceutical Institute, University of Tübingen, Auf der Morgenstelle 8, 72076, Tübingen, Germany
- Pharmazeutische Biologie, Institut für Wirkstoffentwicklung, Universitätsklinikum Leipzig, Eilenburger Strasse 15a, 04317, Leipzig, Germany
| | - Michael Groll
- Chair of Biochemistry, Centre for Protein Assemblies, Technical University Munich, Ernst-Otto-Fischer-Strasse 8, 85748, Garching, Germany
| | - Heike Brötz-Oesterhelt
- Department of Microbial Bioactive Compounds, Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen, Auf der Morgenstelle 28, 72076, Tübingen, Germany
- Cluster of Excellence Controlling Microbes to Fight Infections, University of Tübingen, Auf der Morgenstelle 28, 72076, Tübingen, Germany
| |
Collapse
|
4
|
Beller P, Fink P, Wolf F, Männle D, Helmle I, Kuttenlochner W, Unterfrauner D, Engelbrecht A, Staudt ND, Kulik A, Groll M, Gross H, Kaysser L. Characterization of the cystargolide biosynthetic gene cluster and functional analysis of the methyltransferase CysG. J Biol Chem 2024; 300:105507. [PMID: 38029966 PMCID: PMC10776993 DOI: 10.1016/j.jbc.2023.105507] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Revised: 11/17/2023] [Accepted: 11/21/2023] [Indexed: 12/01/2023] Open
Abstract
Cystargolides are natural products originally isolated from Kitasatospora cystarginea NRRL B16505 as inhibitors of the proteasome. They are composed of a dipeptide backbone linked to a β-lactone warhead. Recently, we identified the cystargolide biosynthetic gene cluster, but systematic genetic analyses had not been carried out because of the lack of a heterologous expression system. Here, we report the discovery of a homologous cystargolide biosynthetic pathway in Streptomyces durhamensis NRRL-B3309 by genome mining. The gene cluster was cloned via transformation-associated recombination and heterologously expressed in Streptomyces coelicolor M512. We demonstrate that it contains all genes necessary for the production of cystargolide A and B. Single gene deletion experiments reveal that only five of the eight genes from the initially proposed gene cluster are essential for cystargolide synthesis. Additional insights into the cystargolide pathway could be obtained from in vitro assays with CysG and chemical complementation of the respective gene knockout. This could be further supported by the in vitro investigation of the CysG homolog BelI from the belactosin biosynthetic gene cluster. Thereby, we confirm that CysG and BelI catalyze a cryptic SAM-dependent transfer of a methyl group that is critical for the construction of the cystargolide and belactosin β-lactone warheads.
Collapse
Affiliation(s)
- Patrick Beller
- Department of Pharmaceutical Biology, Pharmaceutical Institute, University of Tübingen, Tübingen, Germany
| | - Phillipp Fink
- Department of Pharmaceutical Biology, Pharmaceutical Institute, University of Tübingen, Tübingen, Germany
| | - Felix Wolf
- Department of Pharmaceutical Biology, Pharmaceutical Institute, University of Tübingen, Tübingen, Germany
| | - Daniel Männle
- Department of Pharmaceutical Biology, Pharmaceutical Institute, University of Tübingen, Tübingen, Germany
| | - Irina Helmle
- Department of Pharmaceutical Biology, Pharmaceutical Institute, University of Tübingen, Tübingen, Germany
| | - Wolfgang Kuttenlochner
- Department of Bioscience, Center for Protein Assemblies (CPA), TUM School of Natural Sciences, Technical University of Munich, Garching, Germany
| | - Daniel Unterfrauner
- Department of Pharmaceutical Biology, Pharmaceutical Institute, University of Tübingen, Tübingen, Germany
| | - Alicia Engelbrecht
- Department of Pharmaceutical Biology, Pharmaceutical Institute, University of Tübingen, Tübingen, Germany
| | - Nicole D Staudt
- Department of Pharmaceutical Biology, Pharmaceutical Institute, University of Tübingen, Tübingen, Germany
| | - Andreas Kulik
- Interfaculty Institute for Microbiology and Infection Medicine Tübingen (IMIT), Microbial Bioactive Compounds, University of Tübingen, Tübingen, Germany
| | - Michael Groll
- Department of Bioscience, Center for Protein Assemblies (CPA), TUM School of Natural Sciences, Technical University of Munich, Garching, Germany
| | - Harald Gross
- Department of Pharmaceutical Biology, Pharmaceutical Institute, University of Tübingen, Tübingen, Germany
| | - Leonard Kaysser
- Department of Pharmaceutical Biology, Institute for Drug Discovery, University of Leipzig, Leipzig, Germany.
| |
Collapse
|
5
|
Atta H, Alzahaby N, Hamdy NM, Emam SH, Sonousi A, Ziko L. New trends in synthetic drugs and natural products targeting 20S proteasomes in cancers. Bioorg Chem 2023; 133:106427. [PMID: 36841046 DOI: 10.1016/j.bioorg.2023.106427] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2022] [Revised: 01/15/2023] [Accepted: 02/12/2023] [Indexed: 02/19/2023]
Abstract
Cancer is a global health challenge that remains to be a field of extensive research aiming to find new anticancer therapeutics. The 20S proteasome complex is one of the targets of anticancerdrugs, as it is correlated with several cancer types. Herein, we aim to discuss the 20S proteasome subunits and investigatethe currently studied proteasome inhibitors targeting the catalytically active proteasome subunits. In this review, we summarize the proteindegradation mechanism of the 20S proteasome complex and compareit with the 26S proteasome complex. Afterwards, the localization of the 20S proteasome is summarized as well as its use as a diagnosticandprognostic marker. The FDA-approved proteasome inhibitors (PIs) under clinical trials are summarized and their current limited use in solid tumors is also reviewed in addition to the expression of theβ5 subunit in differentcell lines. The review discusses in-silico analysis of the active subunit of the 20S proteasome complex. For development of new proteasome inhibitor drugs, the natural products inhibiting the 20S proteasome are summarized, as well as novel methodologies and challenges for the natural product discovery and current information about the biosynthetic gene clusters encoding them. We herein briefly summarize some resistancemechanismsto the proteasomeinhibitors. Additionally, we focus on the three main classes of proteasome inhibitors: 1] boronic acid, 2] beta-lactone and 3] epoxide inhibitor classes, as well as other PI classes, and their IC50 values and their structure-activity relationship (SAR). Lastly,we summarize several future prospects of developing new proteasome inhibitors towards the treatment of tumors, especially solid tumors.
Collapse
Affiliation(s)
- Hind Atta
- School of Life and Medical Sciences, University of Hertfordshire Hosted By Global Academic Foundation, Egypt
| | - Nouran Alzahaby
- Biochemistry Department, Faculty of Pharmacy, Ain Shams University, Abassia 11566, Cairo, Egypt
| | - Nadia M Hamdy
- Biochemistry Department, Faculty of Pharmacy, Ain Shams University, Abassia 11566, Cairo, Egypt
| | - Soha H Emam
- Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt
| | - Amr Sonousi
- School of Life and Medical Sciences, University of Hertfordshire Hosted By Global Academic Foundation, Egypt; Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt
| | - Laila Ziko
- School of Life and Medical Sciences, University of Hertfordshire Hosted By Global Academic Foundation, Egypt; Biology Department, School of Sciences and Engineering, American University in Cairo, Egypt.
| |
Collapse
|
6
|
Viera CR, Stevens BT, Viera T, Zielinski C, Uranga LA, Rogelj S, Patidar PL, Tello-Aburto R. Cystargolide-based amide and ester Pz analogues as proteasome inhibitors and anti-cancer agents. ROYAL SOCIETY OPEN SCIENCE 2022; 9:220358. [PMID: 36177203 PMCID: PMC9515629 DOI: 10.1098/rsos.220358] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 03/24/2022] [Accepted: 07/29/2022] [Indexed: 06/16/2023]
Abstract
A series of cystargolide-based β-lactone analogues containing nitrogen atoms at the Pz portion of the scaffold were prepared and evaluated as proteasome inhibitors, and for their cytotoxicity profile toward several cancer cell lines. Inclusion of one, two or even three nitrogen atoms at the Pz portion of the cystargolide scaffold is well tolerated, producing analogues with low nanomolar proteasome inhibition activity, in many cases superior to carfilzomib. Additionally, analogue 8g, containing an ester and pyrazine group at Pz, was shown to possess significant activity toward RPMI 8226 cells (IC50 = 21 nM) and to be less cytotoxic toward the normal tissue model MCF10A cells than carfilzomib.
Collapse
Affiliation(s)
- Carlos R. Viera
- Department of Chemistry, New Mexico Institute of Mining and Technology, Socorro, NM 87801, USA
| | - Bradley T. Stevens
- Department of Biology, New Mexico Institute of Mining and Technology, Socorro, NM 87801, USA
| | - Talysa Viera
- Department of Chemistry, New Mexico Institute of Mining and Technology, Socorro, NM 87801, USA
| | - Cameron Zielinski
- Department of Chemical Engineering, New Mexico Institute of Mining and Technology, Socorro, NM 87801, USA
| | - Lee A. Uranga
- Department of Chemistry and Biochemistry, New Mexico State University, Las Cruces, NM 88003, USA
| | - Snezna Rogelj
- Department of Biology, New Mexico Institute of Mining and Technology, Socorro, NM 87801, USA
| | - Praveen L. Patidar
- Department of Chemistry, New Mexico Institute of Mining and Technology, Socorro, NM 87801, USA
| | - Rodolfo Tello-Aburto
- Department of Chemistry and Biochemistry, New Mexico State University, Las Cruces, NM 88003, USA
| |
Collapse
|
7
|
Zhao Y, Xu L, Zhang J, Zhang M, Lu J, He R, Xi J, Zhuang R, Li J, Zhou Y. Optimization of piperidine constructed peptidyl derivatives as proteasome inhibitors. Bioorg Med Chem 2021; 29:115867. [PMID: 33223460 DOI: 10.1016/j.bmc.2020.115867] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2020] [Revised: 10/11/2020] [Accepted: 11/01/2020] [Indexed: 11/28/2022]
Abstract
A series of non-covalent piperidine-containing peptidyl derivatives with various substituents at side chains of different residues were designed, synthesized and evaluated as proteasome inhibitors. After proteasome inhibitory evaluations of all the synthesized target compounds, selected ones were tested for their anti-proliferation activities against three multiple myeloma (MM) cell lines. 8 analogues displayed more potent activities than carfilzomib, and the most promising compound 24 showed IC50 values of 0.8 ± 0.2 nM against 20S proteasome and 8.42 ± 0.74 nM, 7.14 ± 0.52 nM, 14.20 ± 1.08 nM for RPMI 8226, NCI-H929 and MM.1S cell lines, respectively. Additionally, mechanisms of anti-cancer activity of representative compound 24 were further investigated. Apoptosis of RPMI-8226 cells were achieved through accumulating polyubiquitin and inducing the cleavage of caspase and PARP. Besides, half-life in rat plasma of compound 24 was prolonged after optimization, which would be helpful for increasing in vivo activities of this series of derivatives. All the studies confirmed that piperidine-containing non-covalent proteasome inhibitors can be potential leads for anti-MM drug development.
Collapse
Affiliation(s)
- Yanmei Zhao
- Department of Pharmaceutical Preparation, Hangzhou Xixi Hospital, Hangzhou 310023, Zhejiang Province, China
| | - Lei Xu
- National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
| | - Jiankang Zhang
- Department of Pharmaceutical Preparation, Hangzhou Xixi Hospital, Hangzhou 310023, Zhejiang Province, China; School of Medicine, Zhejiang University City College, Hangzhou 310015, Zhejiang Province, China
| | - Mengmeng Zhang
- National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
| | - Jingyi Lu
- School of Medicine, Zhejiang University City College, Hangzhou 310015, Zhejiang Province, China
| | - Ruoyu He
- Department of Pharmaceutical Preparation, Hangzhou Xixi Hospital, Hangzhou 310023, Zhejiang Province, China
| | - Jianjun Xi
- Department of Pharmaceutical Preparation, Hangzhou Xixi Hospital, Hangzhou 310023, Zhejiang Province, China
| | - Rangxiao Zhuang
- Department of Pharmaceutical Preparation, Hangzhou Xixi Hospital, Hangzhou 310023, Zhejiang Province, China.
| | - Jia Li
- National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
| | - Yubo Zhou
- National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
| |
Collapse
|
8
|
Hubbell GE, Tepe JJ. Natural product scaffolds as inspiration for the design and synthesis of 20S human proteasome inhibitors. RSC Chem Biol 2020; 1:305-332. [PMID: 33791679 PMCID: PMC8009326 DOI: 10.1039/d0cb00111b] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2020] [Accepted: 09/01/2020] [Indexed: 12/13/2022] Open
Abstract
The 20S proteasome is a valuable target for the treatment of a number of diseases including cancer, neurodegenerative disease, and parasitic infection. In an effort to discover novel inhibitors of the 20S proteasome, many reseaarchers have looked to natural products as potential leads for drug discovery. The following review discusses the efforts made in the field to isolate and identify natural products as inhibitors of the proteasome. In addition, we describe some of the modifications made to natural products in order to discover more potent and selective inhibitors for potential disease treatment.
Collapse
Affiliation(s)
- Grace E. Hubbell
- Department of Chemistry, Michigan State UniversityEast LansingMI 48823USA
| | - Jetze J. Tepe
- Department of Chemistry, Michigan State UniversityEast LansingMI 48823USA
| |
Collapse
|